Table 2: Differences in mean scores for health-related quality of life (HRQL)* between the treatment groups (after adjustment for differences at baseline) | ||||
Domain | Difference in mean scores | p value§ | ||
Height of season | End of season | Treatment effect | Time effect | |
Sleep impairment
Non-nasal symptoms Practical problems Nasal symptoms Eye symptoms Activity limitations Emotional function | -0.03
0.17 0.15 0.21 -0.27 0.20 0.23 | 0.15
0.09 0.39 0.31 0.04 0.33 0.05 | 0.054
0.274 0.015 0.005 0.614 0.037 0.165 | 0.0037
0.0052 0.0001 0.0035 0.0001 0.0002 0.0003 |
Overall | 0.11 | 0.14 | 0.052 | 0.0001 |
*HRQL determined using Rhinoconjunctivitis Quality of Life Questionnaire3 scores (0 = not bothered, 6 = extremely bothered).
Minimal important difference = 0.5. Positive differences indicate better HRQL for patients in the fluticasone group. §Repeated measures analysis with covariate adjustment for differences in baseline score. |